Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 1997

View Archived Issues

Oral and nasal sumatriptan studied for migraine

Clinical results presented for Knoll's PEG-hirudin

Clinical pharmacokinetics and safety reported for Sankyo's MAO-A inhibitor

Clinical pharmacokinetics and bradycardic activity of S-16257

Pentoxifylline demonstrates gastroprotective effects in patient study

First combination anti-HIV drug approved in U.S.

Symphony discloses AMPA antagonists

Inhibitors of sCD23 production developed at SmithKline Beecham

Zeneca presents new antibacterials active against resistant pathogens

Na+/K+-exchange inhibitors from Fujisawa

Rhone-Poulenc Rorer discloses new AMPA/NMDA receptor antagonists

Antiviral thienoxazinones prepared at SKB

LY-333334: new bone anabolic agent from Lilly

PathoGenesis presents new antimycobacterial agents

Alza to market IVAX urology products in U.S., Canada

Intron A/ribavirin combination for HCV: preliminary phase III results

Seroquel cleared for marketing in U.S.

Amgen to emphasize calcimimetics program; preliminary phase II results reported for R-568

LF-08-0299 both prevents and reverses kidney rejection in dogs

Patient recruitment for verteporfin phase III trials exceeds goals

New class of antifungal agents developed at Glaxo Wellcome

SNX-111 study in head trauma resumed

Bayer evaluates novel heteroaryl oxazolidinones

Pfizer seeks U.S. and European approval for Viagra

Techniclone submits IND for malignant glioma

Clinical results on neuraminidase inhibitor presented at ICAAC

Inex seeks Canadian approval to commence Onco TCS trials for lymphoma

Warner-Lambert reports dihydropyrone HIV protease inhibitors

Canadian regulatory review of modafinil continues

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...